

10/554,186

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 18	CA/CAPplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	4	DEC 18	CA/CAPplus patent kind codes updated
NEWS	5	DEC 18	MARPAT to CA/CAPplus accession number crossover limit increased to 50,000
NEWS	6	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	7	DEC 27	CA/CAPplus enhanced with more pre-1907 records
NEWS	8	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	9	JAN 16	CA/CAPplus Company Name Thesaurus enhanced and reloaded
NEWS	10	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	11	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	12	JAN 22	CA/CAPplus updated with revised CAS roles
NEWS	13	JAN 22	CA/CAPplus enhanced with patent applications from India
NEWS	14	JAN 29	PHAR reloaded with new search and display fields
NEWS	15	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	17	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	18	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	19	FEB 26	MEDLINE reloaded with enhancements
NEWS	20	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	21	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	22	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	23	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS	24	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	25	MAR 16	CASREACT coverage extended
NEWS	26	MAR 20	MARPAT now updated daily
NEWS	27	MAR 22	LWPI reloaded
NEWS	28	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	29	MAR 30	INPADOCDB will replace INPADOC on STN
NEWS	30	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that

10/554,186

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:14:58 ON 12 APR 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:15:08 ON 12 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 APR 2007 HIGHEST RN 929721-97-1

DICTIONARY FILE UPDATES: 11 APR 2007 HIGHEST RN 929721-97-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10554186.str



chain nodes :

21

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 22 23 24 25 26

chain bonds :

5-7 6-8 21-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-9 7-13 8-14 8-18 9-10 10-11 11-12 12-13  
14-15 15-16 16-17 17-18 22-23 22-26 23-24 24-25 25-26

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-8 21-22 22-23 22-26 23-24 24-25 25-26

normalized bonds :

7-9 7-13 8-14 8-18 9-10 10-11 11-12 12-13 14-15 15-16 16-17 17-18

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 21:CLASS  
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom

L1


STRUCTURE UPLOADED

10/554,186

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 16:15:31 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2117 TO ITERATE

94.5% PROCESSED 2000 ITERATIONS

2 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 39580 TO 45100

PROJECTED ANSWERS: 2 TO 129


L2 2 SEA SSS SAM L1

=> d scan


10/554,186

L2 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[1-[[4-(3-phenyl-2-  
quinoxaliny)phenyl)methyl]-2-pyrrolidinyl]-, trifluoroacetate (9CI)  
MF C27 H24 N6 O . x C2 H F3 O2

CM 1



CM 2




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

10/554,186

L2 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 6-Quinoxalinecarboxylic acid, 2-phenyl-3-[4-[[[(3R)-3-[(5-  
thiazolylcarbonyl)amino]-1-pyrrolidinyl)methyl]phenyl]- (9CI)  
MF C30 H25 N5 O3 S  
CI COM

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

10/554,186

=> s l1 sss ful

FULL SEARCH INITIATED 16:15:47 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 41643 TO ITERATE

100.0% PROCESSED 41643 ITERATIONS

47 ANSWERS

SEARCH TIME: 00.00.01

L3

47 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 16:15:52 ON 12 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Apr 2007 VOL 146 ISS 16

FILE LAST UPDATED: 11 Apr 2007 (20070411/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4

9 L3

=> d l4 1-9 bib hitstr

10/554,186

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:433750 CAPLUS

DN 141:7131

TI Preparation of quinazolines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for the treatment of cancer

IN Barnett, Stanley F.; Defeo-Jones, Deborah D.; Hartman, George D.; Huber, Hans E.; Stirdivant, Steven M.; Heimbrosk, David C.

PA USA

SO U.S. Pat. Appl. Publ., 121 pp., which

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004102360	A1	20040527	US 2003-678565	20031003
PRAI	US 2002-422312P	P	20021030		
	US 2003-460911P	P	20030407		
OS	MARPAT 141:7131				

IT 612847-47-9P 612847-51-5P 612847-52-6P  
612847-53-7P 612847-55-9P 612847-57-1P  
612847-59-3P 612847-61-7P 612847-62-8P  
612847-63-9P 612847-65-1P 612847-67-3P  
612847-85-5P 612847-89-9P 612847-91-3P  
612847-93-5P 612847-95-7P 612847-97-9P  
612848-67-6P 616870-54-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antitumor agent; preparation of quinazolines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for treatment of cancer)


RN 612847-47-9 CAPLUS

CN Quinoxaline, 2-[4-[[3-(1H-indol-3-yl)-1-pyrrolidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-46-8

CMF C33 H28 N4




CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/554,186



RN 612847-51-5 CAPLUS


CN Benzamide, 3,4-dichloro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-50-4

CMF C32 H26 Cl2 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-52-6 CAPLUS

CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-53-7 CAPLUS


CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-52-6

CMF C33 H27 N5 O


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-55-9 CAPLUS

CN Benzamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-3-(trifluoromethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-54-8

CMF C33 H27 F3 N4 O

10/554,186


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-57-1 CAPLUS


CN Benzamide, 2,6-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-56-0

CMF C32 H26 F2 N4 O

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/554,186



RN 612847-59-3 CAPLUS


CN Benzamide, 2,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-58-2

CMF C32 H26 F2 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-61-7 CAPLUS


CN Benzamide, 3,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-60-6

CMF C32 H26 F2 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-62-8 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-63-9 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-62-8

CMF C29 H25 N5 O S

Absolute stereochemistry.


10/554,186



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-65-1 CAPLUS


CN 4-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-64-0

CMF C29 H25 N5 O S

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/554,186



RN 612847-67-3 CAPLUS


CN 4-Thiazolidinecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-66-2

CMF C29 H29 N5 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-85-5 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(7-amino-3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-84-4

CMF C29 H26 N6 O S

Absolute stereochemistry.


10/554,186



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-89-9 CAPLUS


CN 6-Quinoxalinecarboxylic acid, 2-phenyl-3-[4-[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-88-8

CMF C30 H25 N5 O3 S

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/554,186



RN 612847-91-3 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-90-2

CMF C28 H24 N6 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-93-5 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-92-4

CMF C28 H24 N6 O S

Absolute stereochemistry.


10/554,186



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-95-7 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-94-6

CMF C28 H24 N6 O S

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/554,186



RN 612847-97-9 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(5-hydroxy-3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612847-96-8

CMF C29 H25 N5 O2 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612848-67-6 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-66-5

CMF C30 H25 N7 O S

Absolute stereochemistry.


10/554,186



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 616870-54-3 CAPLUS


CN 6-Quinoxalinecarboxylic acid, 3-phenyl-2-[4-[[ (3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl)methyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-86-6

CMF C30 H25 N5 O3 S

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/554,186



10/554,186

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2003:836857 CAPLUS  
DN 139:350755  
TI Preparation of fused quinoxaline derivatives as inhibitors of Akt activity  
for treating cancer  
IN Lindsley, Craig W.; Zhao, Zhijian  
PA Merck & Co., Inc., USA  
SO PCT Int. Appl., 127 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086404	A1	20031023	WO 2003-US10447	20030404
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2481241	A1	20031023	CA 2003-2481241	20030404
	AU 2003226271	A1	20031027	AU 2003-226271	20030404
	EP 1494676	A1	20050112	EP 2003-746610	20030404
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	US 2005159422	A1	20050721	US 2003-510066	20030404
	JP 2005528394	T	20050922	JP 2003-583423	20030404
PRAI	US 2002-370833P	P	20020408		
	US 2002-417411P	P	20021009		
	WO 2003-US10447	W	20030404		

OS MARPAT 139:350755

IT 612848-66-5P 612848-67-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused quinoxaline derivs. as inhibitors of Akt activity for treating cancer)

RN 612848-66-5 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612848-67-6 CAPLUS

10/554,186


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-66-5

CMF C30 H25 N7 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/554,186

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:836856 CAPLUS

DN 139:337991

TI Preparation of N-[4-(3-phenylquinoxalin-2-yl)benzyl] substituted sulfonamides as inhibitors of Akt activity

IN Lindsley, Craig W.; Zhao, Zhijian

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 101 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086403	A1	20031023	WO 2003-US10341	20030404
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2480880	A1	20031023	CA 2003-2480880	20030404
	AU 2003230802	A1	20031027	AU 2003-230802	20030404
	EP 1496906	A1	20050119	EP 2003-723899	20030404
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	US 2005130977	A1	20050616	US 2003-510067	20030404
	JP 2005530726	T	20051013	JP 2003-583422	20030404
PRAI	US 2002-370846P	P	20020408		
	WO 2003-US10341	W	20030404		
OS	MARPAT 139:337991				
IT	616224-52-3P				
	RL:	RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)			
		(preparation of N-[4-(3-phenylquinoxalin-2-yl)benzyl] substituted sulfonamides as inhibitors of Akt activity for treating cancer)			
RN	616224-52-3	CAPLUS			
CN	1H-Isoindole-1,3(2H)-dione, 2-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-(9CI) (CA INDEX NAME)				




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:836848 CAPLUS  
 DN 139:350754  
 TI Preparation of 2,3-diphenylquinoxaline derivatives as inhibitors of Akt activity for treating cancer  
 IN Bilodeau, Mark T.; Duggan, Mark E.; Hartnett, John C.; Lindsley, Craig W.; Manley, Peter J.; Wu, Zhicai; Zhao, Zhijian  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 228 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003086394	A1	20031023	WO 2003-US10442	20030404	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	CA 2480800	A1	20031023	CA 2003-2480800	20030404	
	AU 2003223467	A1	20031027	AU 2003-223467	20030404	
	EP 1496896	A1	20050119	EP 2003-719597	20030404	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
	JP 2005533010	T	20051104	JP 2003-583413	20030404	
	US 2005222155	A1	20051006	US 2004-510069	20041004	
PRAI	US 2002-370847P	P	20020408			
	US 2002-417174P	P	20021009			
	WO 2003-US10442	W	20030404			
OS	MARPAT 139:350754					
IT	612847-46-8P 612847-47-9P 612847-50-4P					
	612847-51-5P 612847-52-6P 612847-53-7P					
	612847-54-8P 612847-55-9P 612847-56-0P					
	612847-57-1P 612847-58-2P 612847-59-3P					
	612847-60-6P 612847-61-7P 612847-62-8P					
	612847-63-9P 612847-64-0P 612847-65-1P					
	612847-66-2P 612847-67-3P 612847-84-4P					
	612847-85-5P 612847-86-6P 612847-88-8P					
	612847-89-9P 612847-90-2P 612847-91-3P					
	612847-92-4P 612847-93-5P 612847-94-6P					
	612847-95-7P 612847-96-8P 612847-97-9P					
	616868-00-9P 616870-54-3P					
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)					
	(preparation of 2,3-diphenylquinoxaline derivs. as inhibitors of Akt activity for treating cancer)					
RN	612847-46-8 CAPLUS					
CN	Quinoxaline, 2-[4-[[3-(1H-indol-3-yl)-1-pyrrolidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)					

10/554,186




RN 612847-47-9 CAPLUS

CN Quinoxaline, 2-[4-[[3-(1H-indol-3-yl)-1-pyrrolidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-46-8


CMF C33 H28 N4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-50-4 CAPLUS

CN Benzamide, 3,4-dichloro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny]phenyl)methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/554,186

RN 612847-51-5 CAPLUS


CN Benzamide, 3,4-dichloro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-50-4

CMF C32 H26 Cl2 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-52-6 CAPLUS

CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/554,186

RN 612847-53-7 CAPLUS


CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-52-6

CMF C33 H27 N5 O


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-54-8 CAPLUS

CN Benzamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-55-9 CAPLUS

CN Benzamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-3-(trifluoromethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)


10/554,186

CM 1

CRN 612847-54-8

CMF C33 H27 F3 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-56-0 CAPLUS

CN Benzamide, 2,6-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinylyl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-57-1 CAPLUS


CN Benzamide, 2,6-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinylyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

10/554,186


CRN 612847-56-0  
CMF C32 H26 F2 N4 O

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 612847-58-2 CAPLUS  
CN Benzamide, 2,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-59-3 CAPLUS  
CN Benzamide, 2,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-58-2

10/554,186

CMF C32 H26 F2 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-60-6 CAPLUS

CN Benzamide, 3,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-61-7 CAPLUS


CN Benzamide, 3,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

10/554,186


CRN 612847-60-6  
CMF C32 H26 F2 N4 O

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 612847-62-8 CAPLUS  
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-63-9 CAPLUS  
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-62-8  
CMF C29 H25 N5 O S



10/554,186


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-64-0 CAPLUS

CN 4-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-65-1 CAPLUS


CN 4-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-64-0

CMF C29 H25 N5 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-66-2 CAPLUS

CN 4-Thiazolidinecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-67-3 CAPLUS

CN 4-Thiazolidinecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-66-2

CMF C29 H29 N5 O S

Absolute stereochemistry.


10/554,186



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-84-4 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(7-amino-3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-85-5 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(7-amino-3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-84-4

CMF C29 H26 N6 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-86-6 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 3-phenyl-2-[4-[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612847-88-8 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 2-phenyl-3-[4-[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-89-9 CAPLUS


CN 6-Quinoxalinecarboxylic acid, 2-phenyl-3-[4-[[ (3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-88-8

CMF C30 H25 N5 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-90-2 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-91-3 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-90-2

CMF C28 H24 N6 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 612847-92-4 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612847-93-5 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-92-4

CMF C28 H24 N6 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 612847-94-6 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/554,186



RN 612847-95-7 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-94-6

CMF C28 H24 N6 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 612847-96-8 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(5-hydroxy-3-phenyl-2-quinoxaliny]phenyl)methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 612847-97-9 CAPLUS  
 CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(5-hydroxy-3-phenyl-2-quinoxalinyloxy)methyl]phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 612847-96-8  
 CMF C29 H25 N5 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 616868-00-9 CAPLUS  
 CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[1-[[4-(3-phenyl-2-quinoxalinyloxy)methyl]phenyl]methyl]-2-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


10/554,186

CRN 616867-99-3  
CMF C27 H24 N6 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 616870-54-3 CAPLUS  
CN 6-Quinoxalinecarboxylic acid, 3-phenyl-2-[4-[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-86-6  
CMF C30 H25 N5 O3 S

Absolute stereochemistry.




CM 2

CRN 76-05-1

10/554,186

CMF C2 H F3 O2



RE.CNT 1      THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/554,186


L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2003:818232 CAPLUS  
DN 139:323527  
TI Preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for  
the treatment of cancer  
IN Barnett, Stanley F.; Defeo-Jones, Deborah; Haskell, Kathleen M.; Huber,  
Hans E.; Nahas, Deborah D.; Lindsley, Craig W.; Zhao, Zhijian; Hartman,  
George D.  
PA Merck & Co., Inc., USA  
SO PCT Int. Appl., 170 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084473	A2	20031016	WO 2003-US10632	20030404
	WO 2003084473	A3	20040212		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,				
	LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003226301	A1	20031020	AU 2003-226301	20030404
	US 2006142178	A1	20060629	US 2004-510068	20041004
PRAI	US 2002-370827P	P	20020408		
	US 2002-417202P	P	20021009		
	WO 2003-US10632	W	20030404		
IT	612847-47-9P 612847-51-5P 612847-53-7P				
	612847-55-9P 612847-57-1P 612847-59-3P				
	612847-61-7P 612847-63-9P 612847-65-1P				
	612847-67-3P 612847-85-5P 612847-87-7P				
	612847-89-9P 612847-91-3P 612847-93-5P				
	612847-95-7P 612847-97-9P 612848-67-6P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU				
	(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES				
	(Uses)				
	(preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for				
	the treatment of cancer)				
RN	612847-47-9 CAPLUS				
CN	Quinoxaline, 2-[4-[[3-(1H-indol-3-yl)-1-pyrrolidinyl]methyl]phenyl]-3-				
	phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)				

CM 1

CRN 612847-46-8

CMF C33 H28 N4




10/554,186

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-51-5 CAPLUS


CN Benzamide, 3,4-dichloro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)]phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-50-4

CMF C32 H26 Cl2 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-53-7 CAPLUS


CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)]phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

10/554,186


CRN 612847-52-6  
CMF C33 H27 N5 O

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 612847-55-9 CAPLUS  
CN Benzamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidiny]-3-(trifluoromethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-54-8  
CMF C33 H27 F3 N4 O


Absolute stereochemistry.



CM 2

10/554,186

CRN 76-05-1  
CMF C2 H F3 O2




RN 612847-57-1 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)]phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 612847-56-0  
CMF C32 H26 F2 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 612847-59-3 CAPLUS  
CN Benzamide, 2,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)]phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-58-2  
CMF C32 H26 F2 N4 O

Absolute stereochemistry.


10/554,186



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-61-7 CAPLUS


CN Benzamide, 3,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-60-6

CMF C32 H26 F2 N4 O

Absolute stereochemistry.




CM 2

CRN 76-05-1



10/554,186

CMF C2 H F3 O2



RN 612847-63-9 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-62-8

CMF C29 H25 N5 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-65-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-64-0

CMF C29 H25 N5 O S

Absolute stereochemistry.


10/554,186



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-67-3 CAPLUS


CN 4-Thiazolidinecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyloxy)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-66-2

CMF C29 H29 N5 O S

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/554,186



RN 612847-85-5 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(7-amino-3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-84-4

CMF C29 H26 N6 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-87-7 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 3-phenyl-2-[4-[[[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 612847-86-6

CMF C30 H25 N5 O3 S

Absolute stereochemistry.


10/554,186



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-89-9 CAPLUS


CN 6-Quinoxalinecarboxylic acid, 2-phenyl-3-[4-[[ (3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl)methyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-88-8

CMF C30 H25 N5 O3 S

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/554,186



RN 612847-91-3 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[3,4-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-90-2

CMF C28 H24 N6 O S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-93-5 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenylpyrido[2,3-b]pyrazin-2-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612847-92-4

CMF C28 H24 N6 O S

Absolute stereochemistry.


10/554,186



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-95-7 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(2-phenylpyrido[2,3-b]pyrazin-3-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-94-6

CMF C28 H24 N6 O S

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/554,186



RN 612847-97-9 CAPLUS


CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(5-hydroxy-3-phenyl-2-quinoxaliny)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612847-96-8

CMF C29 H25 N5 O2 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612848-67-6 CAPLUS

CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 612848-66-5

CMF C30 H25 N7 O S

Absolute stereochemistry.


10/554,186



CM 2

CRN 76-05-1


CMF C2 H F3 O2






L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1993:517279 CAPLUS  
 DN 119:117279  
 TI A process for the preparation of thieno[4,5-g] quinoxaline amebicides  
 IN Venugopalan, Bindumadhavan; Bapat, Chintamani Prabhakar; Chatterjee,  
 Deepak Kumar; De Souza, Noel John; Rupp, Richard Helmut  
 PA Hoechst India Ltd., India  
 SO Indian, 26 pp.  
 CODEN: INXXAP  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	IN 167425	A1	19901027	IN 1988-BO46	19880226
PRAI	IN 1988-BO46		19880226		
OS	MARPAT 119:117279				
IT	127692-48-2P 149397-06-8P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and amebicidal activity of)				
RN	127692-48-2 CAPLUS				
CN	Pyrrolidine, 1-[[[5,9-dimethoxy-8-methyl-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]thieno[2,3-g]quinoxalin-7-yl]carbonyl]- (9CI) (CA INDEX NAME)				




RN 149397-06-8 CAPLUS  
 CN Thieno[2,3-g]quinoxaline-7-carboxylic acid, 5,9-dimethoxy-8-methyl-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 127692-35-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and hydrolysis of, in amebicide preparation)  
 RN 127692-35-7 CAPLUS  
 CN Thieno[2,3-g]quinoxaline-7-carboxylic acid, 5,9-dimethoxy-8-methyl-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)


10/554,186




10/554,186

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1992:41482 CAPLUS  
DN 116:41482  
TI Preparation of 5,8-dimethoxy-2,3-bis(4-aminomethylphenyl)quinoxalines as  
protozoacides  
IN Venugopalan, Bindumadhavan; Chatterjee, Deepak Kumar; De Souza, Noel John;  
Rupp, Richard Helmut  
PA Hoechst India Ltd., India  
SO Indian, 17 pp.  
CODEN: INXXAP  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO. -----	KIND ----	DATE -----	APPLICATION NO. -----	DATE -----
PI	IN 166761	A1	19900714	IN 1987-BO125	19870410
PRAI	IN 1987-BO125		19870410		
OS	MARPAT 116:41482				
IT	136270-45-6P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation, as protozoacide)				
RN	136270-45-6 CAPLUS				
CN	Quinoxaline, 5,8-dimethoxy-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)				




L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1991:559095 CAPLUS  
DN 115:159095  
TI Synthesis and antiamebic activity of 2,3-diaryl-5,8-dimethoxyquinoxalines  
AU Venugopalan, B.; Sureshi, S.; Karnik, P. J.; De Souza, N. J.; Chatterjee, D. K.; Iyer, S. N.  
CS Dep. Chem., Hoechst Indian Ltd., Bombay, 400 080, India  
SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1991), 30B(8), 777-83  
CODEN: IJSBDB; ISSN: 0376-4699  
DT Journal  
LA English  
IT 136270-45-6P 137389-47-0P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and antiamebic activity of)  
RN 136270-45-6 CAPLUS  
CN Quinoxaline, 5,8-dimethoxy-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]- (9CI)  
(CA INDEX NAME)




RN 137389-47-0 CAPLUS  
CN Quinoxaline, 6,7-dimethoxy-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]- (9CI)  
(CA INDEX NAME)



L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1990:423849 CAPLUS  
 DN 113:23849  
 TI Synthesis of thieno[3,2-g]quinoxalines as potential amebicides  
 AU Venugopalan, B.; Bapat, C. P.; De Souza, N. J.; Chatterjee, D. K.; Iyer, N. J.  
 CS Res. Cent., Hoechst India Ltd., Bombay, 400080, India  
 SO European Journal of Medicinal Chemistry (1989), 24(6), 611-14  
 CODEN: EJMCA5; ISSN: 0223-5234  
 DT Journal  
 LA English  
 OS CASREACT 113:23849  
 IT 127692-35-7P 127692-48-2P 127692-49-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and amebicide activity of)  
 RN 127692-35-7 CAPLUS  
 CN Thieno[2,3-g]quinoxaline-7-carboxylic acid, 5,9-dimethoxy-8-methyl-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 127692-48-2 CAPLUS  
 CN Pyrrolidine, 1-[[5,9-dimethoxy-8-methyl-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]thieno[2,3-g]quinoxalin-7-yl]carbonyl]- (9CI)  
 (CA INDEX NAME)



RN 127692-49-3 CAPLUS  
 CN Piperidine, 1-[[5,9-dimethoxy-8-methyl-2,3-bis[4-(1-pyrrolidinylmethyl)phenyl]thieno[2,3-g]quinoxalin-7-yl]carbonyl]- (9CI)  
 (CA INDEX NAME)

10/554,186



10/554,186

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

33.05

205.36

STN INTERNATIONAL LOGOFF AT 16:16:21 ON 12 APR 2007

10/554,186

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 Jul 12 BEILSTEIN enhanced with new display and select options,  
resulting in a closer connection to BABS  
NEWS 4 AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display  
fields  
NEWS 5 AUG 02 Cplus and CA patent records enhanced with European and Japan  
Patent Office Classifications  
NEWS 6 AUG 02 The Analysis Edition of STN Express with Discover!  
(Version 7.01 for Windows) now available  
NEWS 7 AUG 27 BIOCOMMERCE: Changes and enhancements to content coverage  
NEWS 8 AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added for legal  
status data from INPADOC  
NEWS 9 SEP 01 INPADOC: New family current-awareness alert (SDI) available  
NEWS 10 SEP 01 New pricing for the Save Answers for SciFinder Wizard within  
STN Express with Discover!  
NEWS 11 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX  
NEWS 12 SEP 14 STN Patent Forum to be held October 13, 2004, in Iselin, NJ  
NEWS 13 SEP 27 STANDARDS will no longer be available on STN  
NEWS 14 SEP 27 SWETSCAN will no longer be available on STN  
NEWS 15 SEP 30 STN downtime scheduled October 2-3, 2004  
  
NEWS EXPRESS JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:59:56 ON 03 OCT 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:00:10 ON 03 OCT 2004



10/554,186

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 OCT 2004 HIGHEST RN 755753-81-2  
DICTIONARY FILE UPDATES: 1 OCT 2004 HIGHEST RN 755753-81-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> .....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\STNEXP4\QUERIES\504012157.str

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> d l1

L1 HAS NO ANSWERS

L1 STR

/ Structure 1 in file .gra /

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 12:00:36 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 375 TO ITERATE

100.0% PROCESSED 375 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 6339 TO 8661

PROJECTED ANSWERS: 1 TO 80

L3 1 SEA SSS SAM L1

=> d scan

10/554,186

L3 1 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
IN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-,  
trifluoroacetate (9CI)  
MF C33 H35 N5 O2 . x C2 H F3 O2

CM 1

/ Structure 2 in file .gra /

CM 2

/ Structure 3 in file .gra /

ALL ANSWERS HAVE BEEN SCANNED

10/554,186

=> s l1 sss ful

FULL SEARCH INITIATED 12:00:54 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 7252 TO ITERATE

100.0% PROCESSED 7252 ITERATIONS  
SEARCH TIME: 00.00.01

33 ANSWERS

L4 33 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.42

155.63

FILE 'CAPLUS' ENTERED AT 12:01:00 ON 03 OCT 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Oct 2004 VOL 141 ISS 15

FILE LAST UPDATED: 1 Oct 2004 (20041001/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4

L5 3 L4

=> d l5 1-3 bib hitstr

10/554,186

L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2004:433750 CAPLUS  
DN 141:7131  
TI Preparation of quinazolines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for the treatment of cancer  
IN Barnett, Stanley F.; Defeo-Jones, Deborah D.; Hartman, George D.; Huber, Hans E.; Stirdivant, Steven M.; Heimbrook, David C.  
PA USA  
SO U.S. Pat. Appl. Publ., 121 pp., which  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	----	-----	-----
PI	US 2004102360	A1	20040527	US 2003-678565	20031003
PRAI	US 2002-422312P	P	20021030		
	US 2003-460911P	P	20030407		

OS MARPAT 141:7131

IT 612847-15-1P 612847-16-2P 612847-17-3P  
612847-18-4P 612847-19-5P 612847-20-8P  
612848-78-9P 616873-13-3P 616873-19-9P  
616873-21-3P 616873-27-9P 616873-29-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antitumor agent; preparation of quinazolines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for treatment of cancer)

RN 612847-15-1 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(2-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 4 in file .gra /

RN 612847-16-2 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(2-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-15-1

CMF C33 H35 N5 O2

/ Structure 5 in file .gra /

CM 2

CRN 76-05-1

CMF C2 H F3 O2

/ Structure 6 in file .gra /

RN 612847-17-3 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-indol-3-ylmethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA

10/554,186

INDEX NAME)

/ Structure 7 in file .gra /

RN 612847-18-4 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-indol-3-ylmethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-17-3  
CMF C38 H34 N6 O2

/ Structure 8 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 9 in file .gra /

RN 612847-19-5 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-indol-3-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 10 in file .gra /

RN 612847-20-8 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-indol-3-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-19-5  
CMF C38 H34 N6 O2

/ Structure 11 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 12 in file .gra /

RN 612848-78-9 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(2-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/554,186

/ Structure 13 in file .gra /

RN 616873-13-3 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(2-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-78-9  
CMF C33 H35 N5 O2

/ Structure 14 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 15 in file .gra /

RN 616873-19-9 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-6-oxo-3-phenyl-5-(phenylmethyl)pyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-18-8  
CMF C36 H33 N5 O2

/ Structure 16 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 17 in file .gra /

RN 616873-21-3 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-20-2  
CMF C33 H35 N5 O2

/ Structure 18 in file .gra /

CM 2

CRN 76-05-1

10/554,186

CMF C2 H F3 O2

/ Structure 19 in file .gra /

RN 616873-27-9 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-imidazol-4-ylmethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-26-8

CMF C33 H31 N7 O2

/ Structure 20 in file .gra /

CM 2

CRN 76-05-1

CMF C2 H F3 O2

/ Structure 21 in file .gra /

RN 616873-29-1 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-(4,5-dihydro-6-methyl-5-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-28-0

CMF C30 H29 N5 O2

/ Structure 22 in file .gra /

CM 2

CRN 76-05-1

CMF C2 H F3 O2

/ Structure 23 in file .gra /

10/554,186

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2003:836759 CAPLUS  
DN 139:350753  
TI Preparation of 2,3-diphenylpyrazine derivatives as inhibitors of Akt  
activity for treating cancer  
IN Duggan, Mark E.; Lindsley, Craig W.; Zhao, Zhijian  
PA Merck & Co., Inc., USA  
SO PCT Int. Appl., 119 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086279	A2	20031023	WO 2003-US10342	20030404
	WO 2003086279	A3	20040108		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2002-370842P P 20020408

OS MARPAT 139:350753

IT 612847-15-1P 612847-16-2P 612847-17-3P  
612847-18-4P 612847-19-5P 612847-20-8P  
612847-21-9P 612847-22-0P 612847-23-1P  
612847-24-2P 612847-25-3P 612847-26-4P  
612848-78-9P 616873-13-3P 616873-14-4P  
616873-15-5P 616873-16-6P 616873-17-7P  
616873-18-8P 616873-19-9P 616873-20-2P  
616873-21-3P 616873-22-4P 616873-23-5P  
616873-24-6P 616873-25-7P 616873-26-8P  
616873-27-9P 616873-28-0P 616873-29-1P  
616873-30-4P 616873-31-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,3-diphenylpyrazine derivs. as inhibitors of Akt activity for treating cancer)

RN 612847-15-1 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(2-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 24 in file .gra /

RN 612847-16-2 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(2-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-15-1

CMF C33 H35 N5 O2



10/554,186

/ Structure 25 in file .gra /

CM 2

CRN 76-05-1

CMF C2 H F3 O2

/ Structure 26 in file .gra /

RN 612847-17-3 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-indol-3-ylmethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 27 in file .gra /

RN 612847-18-4 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-indol-3-ylmethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-17-3

CMF C38 H34 N6 O2

/ Structure 28 in file .gra /

CM 2

CRN 76-05-1

CMF C2 H F3 O2

/ Structure 29 in file .gra /

RN 612847-19-5 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-indol-3-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 30 in file .gra /

RN 612847-20-8 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-indol-3-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-19-5

CMF C38 H34 N6 O2

/ Structure 31 in file .gra /

10/554,186

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 32 in file .gra /

RN 612847-21-9 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-5-oxo-3-phenyl-6-(phenylmethyl)pyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI)  
(CA INDEX NAME)

/ Structure 33 in file .gra /

RN 612847-22-0 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-5-oxo-3-phenyl-6-(phenylmethyl)pyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-21-9  
CMF C36 H33 N5 O2

/ Structure 34 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 35 in file .gra /

RN 612847-23-1 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 36 in file .gra /

RN 612847-24-2 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-23-1  
CMF C33 H35 N5 O2

/ Structure 37 in file .gra /

CM 2

10/554,186

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 38 in file .gra /

RN 612847-25-3 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-imidazol-4-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI)  
(CA INDEX NAME)

/ Structure 39 in file .gra /

RN 612847-26-4 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-imidazol-4-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-,  
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-25-3  
CMF C33 H31 N7 O2

/ Structure 40 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 41 in file .gra /

RN 612848-78-9 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(2-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 42 in file .gra /

RN 616873-13-3 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(2-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-,  
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-78-9  
CMF C33 H35 N5 O2

/ Structure 43 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

10/554,186

/ Structure 44 in file .gra /

RN 616873-14-4 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(4,5-dihydro-5-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 45 in file .gra /

RN 616873-15-5 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(4,5-dihydro-5-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-14-4  
CMF C29 H27 N5 O2

/ Structure 46 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 47 in file .gra /

RN 616873-16-6 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(1,6-dihydro-6-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 48 in file .gra /

RN 616873-17-7 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(1,6-dihydro-6-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-16-6  
CMF C29 H27 N5 O2

/ Structure 49 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 50 in file .gra /

10/554,186

RN 616873-18-8 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-6-oxo-3-phenyl-5-(phenylmethyl)pyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI)  
(CA INDEX NAME)

/ Structure 51 in file .gra /

RN 616873-19-9 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-6-oxo-3-phenyl-5-(phenylmethyl)pyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-,  
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-18-8  
CMF C36 H33 N5 O2

/ Structure 52 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 53 in file .gra /

RN 616873-20-2 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 54 in file .gra /

RN 616873-21-3 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-,  
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-20-2  
CMF C33 H35 N5 O2

/ Structure 55 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 56 in file .gra /

RN 616873-22-4 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(hydroxymethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA

10/554,186

INDEX NAME)

/ Structure 57 in file .gra /

RN 616873-23-5 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(hydroxymethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 616873-22-4

CMF C30 H29 N5 O3

/ Structure 58 in file .gra /

CM 2

CRN 76-05-1

CMF C2 H F3 O2

/ Structure 59 in file .gra /

RN 616873-24-6 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(hydroxymethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 60 in file .gra /

RN 616873-25-7 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(hydroxymethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 616873-24-6

CMF C30 H29 N5 O3

/ Structure 61 in file .gra /

CM 2

CRN 76-05-1

CMF C2 H F3 O2

/ Structure 62 in file .gra /

RN 616873-26-8 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-imidazol-4-ylmethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/554,186

/ Structure 63 in file .gra /

RN 616873-27-9 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-imidazol-4-ylmethyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-26-8  
CMF C33 H31 N7 O2

/ Structure 64 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 65 in file .gra /

RN 616873-28-0 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(4,5-dihydro-6-methyl-5-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 66 in file .gra /

RN 616873-29-1 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(4,5-dihydro-6-methyl-5-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-28-0  
CMF C30 H29 N5 O2

/ Structure 67 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 68 in file .gra /

RN 616873-30-4 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(1,6-dihydro-5-methyl-6-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

/ Structure 69 in file .gra /

RN 616873-31-5 CAPLUS

10/554,186

CN 2H-Benzimidazol-2-one, 1-[1-[[4-(1,6-dihydro-5-methyl-6-oxo-3-phenylpyrazinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616873-30-4

CMF C30 H29 N5 O2

/ Structure 70 in file .gra /

CM 2

CRN 76-05-1

CMF C2 H F3 O2

/ Structure 71 in file .gra /



10/554,186

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2003:818232 CAPLUS  
DN 139:323527  
TI Preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for  
the treatment of cancer  
IN Barnett, Stanley F.; Defeo-Jones, Deborah; Haskell, Kathleen M.; Huber,  
Hans E.; Nahas, Deborah D.; Lindsley, Craig W.; Zhao, Zhijian; Hartman,  
George D.  
PA Merck & Co., Inc., USA  
SO PCT Int. Appl., 170 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084473	A2	20031016	WO 2003-US10632	20030404
	WO 2003084473	A3	20040212		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2002-370827P	P	20020408		
	US 2002-417202P	P	20021009		
IT	612847-16-2P 612847-18-4P 612847-20-8P 612847-22-0P 612847-24-2P 612847-26-4P 612848-79-0P				
	RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
		(preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer)			
RN	612847-16-2	CAPLUS			
CN	2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(2-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)				
CM	1				
CRN	612847-15-1				
CMF	C33 H35 N5 O2				

/ Structure 72 in file .gra /

CM 2  
CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 73 in file .gra /

RN 612847-18-4 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1H-indol-3-ylmethyl)-5-oxo-

10/554,186

3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-,  
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-17-3

CMF C38 H34 N6 O2

/ Structure 74 in file .gra /

CM 2

CRN 76-05-1

CMF C2 H F3 O2

/ Structure 75 in file .gra /

RN 612847-20-8 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-indol-3-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-,  
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-19-5

CMF C38 H34 N6 O2

/ Structure 76 in file .gra /

CM 2

CRN 76-05-1

CMF C2 H F3 O2

/ Structure 77 in file .gra /

RN 612847-22-0 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-5-oxo-3-phenyl-6-(phenylmethyl)pyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-,  
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-21-9

CMF C36 H33 N5 O2

/ Structure 78 in file .gra /

CM 2

CRN 76-05-1

CMF C2 H F3 O2

/ Structure 79 in file .gra /

10/554,186

RN 612847-24-2 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[4,5-dihydro-6-(1-methylpropyl)-5-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-23-1  
CMF C33 H35 N5 O2

/ Structure 80 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 81 in file .gra /

RN 612847-26-4 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(1H-imidazol-4-ylmethyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-25-3  
CMF C33 H31 N7 O2

/ Structure 82 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

/ Structure 83 in file .gra /

RN 612848-79-0 CAPLUS  
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[1,6-dihydro-5-(2-methylpropyl)-6-oxo-3-phenylpyrazinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612848-78-9  
CMF C33 H35 N5 O2

/ Structure 84 in file .gra /

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

10/554,186

/ Structure 85 in file .gra /

10/554,186

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

10.25

165.88

STN INTERNATIONAL LOGOFF AT 12:01:24 ON 03 OCT 2004